Skip to main content
ADME and Bioanalytical Sciences
Cell Based Assays
Fragment and Compound Screening
Integrated Drug Discovery Services
Protein Expression and Purification Services
Hit to Lead
CNS Drug Discovery
Targeted Protein Degradation
Approaches & Techniques
CDH (Target Gene Fragmentation)
Cryogenic Electron Microscopy (Cryo-EM)
Differential Scanning Fluorimetry (DSF) and nanoDSF Services
Fragment Based Drug Discovery (FBDD)
High Throughput Screening
Isothermal Titration Calorimetry (ITC)
MicroScale Thermophoresis (MST) Services
PoLiPa (Membrane Protein Solubilisation)
Structure Based Drug Design (SBDD)
Surface Plasmon Resonance (SPR)
Presentations & Videos
News & Events
Delivering innovative science
Our highly experienced and expert scientific team has an unrivalled track record of solving research challenges, delivering successful outcomes efficiently, and therefore setting the highest possible benchmark in medicines research.
MAP4K4: Kinase inhibitors for cardioprotection following heart attacks
Domainex designed novel, potent, highly selective, small-molecule inhibitors of MAP4K4, with potential cardioprotective drug properties.
Tankyrase: Inhibitors for the treatment of solid tumours
Domainex employed its LeadBuilder virtual screening technology to identify tankyrase inhibitors from which pre-clinical development candidates emerged.
Der p 1: Protease Inhibitors for the treatment of asthma
Domainex collaborated with St George’s University London & the University of Manchester on a programme of drug discovery which led to the successfully nomination of a candidate drug.
TBK1/IKKε: Kinase inhibitors for the treatment of interferonopathies
Domainex identified a drug candidate DMXD-011, a first-in-class small-molecule orally bioavailable inhibitor of TBK1/IKKε
FLIPP-FADD: PPI inhibitors for the treatment of solid tumours
Domainex and Queen's University Belfast have discovered the world’s first inhibitors of FLIP-FADD and produced viable leads for drug candidate selection
Ras: PPI inhibitors for the treatment of cancer
Domainex used its extensive experience of fragment- & structure-based drug design to develop a lead molecule with strong binding to RAS, an oncology target.
G9a: Lysine Methyltransferase Inhibitors for the Treatment of Cancer
Starting from a LeadBuilder screen we identified novel potent inhibitors of G9a, which have potential to be developed as treatments for a range of solid tumours.
G9a: A fragment-based drug design (FBDD) programme to identify lysine methyltransferase inhibitors for the treatment of cancer
Domainex identified several highly efficient fragment hits and after one round of elaboration a 10-fold increase in affinity was achieved.
VEGF/NRP1: PPI inhibitors for the treatment of solid tumours
We designed and synthesised EG00229, the first small-molecule ligand of the VEGF-A165 receptor NRP1.
CDH Case Studies
Case studies using our patented combinatorial domain hunting (CDH) technology, which has been applied to over 60 targets in a wide range of target classes.
Neurotensin Receptor 1: Purification by PoLiPa
We used the neurotensin receptor 1 (NTSR1) as a proof-of-concept study to demonstrate the effectiveness of our PoLiPa GPCR purification process.
CD73: A structural biology case study
Domainex established biochemical and ligand-binding assays for CD73 and the expressed protein was also used successfully in X-ray crystallography studies.
Start your next project with Domainex
Contact one of our experts today